August 18, 2009 - Basilea Pharmaceutica Ltd. announces that the company was notified today that the U.S. FDA issued to Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD) a Warning Letter related to clinical trials for ceftobiprole for the treatment of complicated skin and skin structure infections.
The details can be read here.
No comments:
Post a Comment